Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Mol Neurobiol ; 61(9): 6435-6452, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38307967

RESUMEN

Mitochondrial dysfunction plays a key role in the development of neurodegenerative disorders. In contrast, the regulation of the endocannabinoid system has been shown to promote neuroprotection in different neurotoxic paradigms. The existence of an active form of the cannabinoid receptor 1 (CB1R) in mitochondrial membranes (mitCB1R), which might exert its effects through the same signaling mechanisms as the cell membrane CB1R, has been shown to regulate mitochondrial activity. Although there is evidence suggesting that some cannabinoids may induce protective effects on isolated mitochondria, substantial evidence on the role of cannabinoids in mitochondria remains to be explored. In this work, we developed a toxic model of mitochondrial dysfunction induced by exposure of brain mitochondria to the succinate dehydrogenase inhibitor 3-nitropropionic acid (3-NP). Mitochondria were also pre-incubated with the endogenous agonist anandamide (AEA) and the synthetic CB1R agonist WIN 55212-2 to evaluate their protective effects. Mitochondrial reduction capacity, reactive oxygen species (ROS) formation, and mitochondrial swelling were assessed as toxic markers. While 3-NP decreased the mitochondrial reduction capacity and augmented mitochondrial ROS formation and swelling, both AEA and WIN 55212-2 ameliorated these toxic effects. To explore the possible involvement of mitCB1R activation on the protective effects of AEA and WIN 55212-2, mitochondria were also pre-incubated in the presence of the selective CB1R antagonist AM281, which completely reverted the protective effects of the cannabinoids to levels similar to those evoked by 3-NP. These results show partial protective effects of cannabinoids, suggesting that mitCB1R activation may be involved in the recovery of compromised mitochondrial activity, related to reduction of ROS formation and further prevention of mitochondrial swelling.


Asunto(s)
Ácidos Araquidónicos , Benzoxazinas , Encéfalo , Endocannabinoides , Mitocondrias , Morfolinas , Naftalenos , Fármacos Neuroprotectores , Nitrocompuestos , Alcamidas Poliinsaturadas , Propionatos , Ratas Wistar , Especies Reactivas de Oxígeno , Animales , Nitrocompuestos/toxicidad , Propionatos/farmacología , Propionatos/toxicidad , Mitocondrias/metabolismo , Mitocondrias/efectos de los fármacos , Endocannabinoides/metabolismo , Endocannabinoides/farmacología , Benzoxazinas/farmacología , Ácidos Araquidónicos/farmacología , Morfolinas/farmacología , Especies Reactivas de Oxígeno/metabolismo , Alcamidas Poliinsaturadas/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Masculino , Fármacos Neuroprotectores/farmacología , Naftalenos/farmacología , Dilatación Mitocondrial/efectos de los fármacos , Ratas , Receptor Cannabinoide CB1/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA